Research
Hormonal
Leptin treatment reduces serum resistin and resistin mRNA expression in obese mice, an effect that is independent of weight loss or food intake, suggesting leptin directly regulates resistin to improve insulin sensitivity.
In obese individuals, hormonal signals like leptin may play a key role in regulating resistin levels, independent of weight loss. This suggests that improving leptin sensitivity through lifestyle changes might help normalize resistin levels.
GoodSupportsHIGH confidence
Leptin treatment significantly decreased food intake, body weight, and percentage of fat... Moreover, leptin decreased insulin, glucose, and triglyceride levels... Resistin mRNA expression, serum level, and WAT resistin protein decreased in parallel with the fall in glucose and insulin in leptin-treated animals. Pair-feeding decreased body weight and fat but had little effect on glucose, insulin, and triglyceride levels... pair-feeding had no significant effect on resistin mRNA expression and protein levels
Why this rating
Robust animal study with clear controls (pair-feeding vs. leptin injection).
Source
Regulation of Resistin Expression and Circulating Levels in Obesity, Diabetes, and Fasting
Michael W. Rajala et al. · Diabetes · 2004
DOI 10.2337/diabetes.53.7.1671
mechanism_onlyCited 350×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In obese and diabetic rodent models, circulating resistin levels are elevated and positively correlated with insulin, glucose, and lipids, despite suppressed resistin mRNA expression in adipose tissue, indicating that nutritional regulation of resistin is mediated by insulin and glucose.Good
- Hyperinsulinemia and hyperglycemia directly increase resistin mRNA expression and serum levels in wild-type mice, indicating that insulin and glucose are key regulators of resistin production.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →